SS
CRVS icon

SBI Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

SBI Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7K Hold
1,004
– – ﹤0.01% 1582
2025
Q4 		$7.73K Sell
1,004
-2
-0.2% -$16 ﹤0.01% 1835
2025
Q3 		$7.41K Buy
1,006
+6
+0.6% +$31 ﹤0.01% 1892
2025
Q2 		$4K Hold
1,000
– – ﹤0.01% 2094
2025
Q1 		$3.18K Hold
1,000
– – ﹤0.01% 2080
2024
Q4 		$5.35K Buy
+1,000
New +$7.46K ﹤0.01% 1902

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SBI Securities's CRVS Position: Q1 2026 in Review

SBI Securities held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 1,004 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

SBI Securities first reported a position in CRVS in Q4 2024 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • SBI Securities held 1,004 shares of Corvus Pharmaceuticals worth $14.7K as of Q1 2026.
  • SBI Securities left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1582 holding.
  • SBI Securities first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.